Caveolin regulates Kv1.5 trafficking to cholesterol-rich membrane microdomains

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 678-685

  McEwen, Dyke P ^a   Li, Qiuju ^a   Jackson, Sajida ^a   Jenkins, Paul M ^a   Martens, Jeffrey R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CHOLESTEROL; POTASSIUM CHANNEL KV1.5;

ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE DEPOLARIZATION; CELL SURFACE; MEMBRANE CHANNEL; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; CAVEOLIN 1; CAVEOLIN 3; CAVEOLINS; CELL LINE; CHOLESTEROL; DNA, COMPLEMENTARY; ELECTROPHYSIOLOGY; FEMALE; IMMUNOHISTOCHEMISTRY; KV1.5 POTASSIUM CHANNEL; MEMBRANE MICRODOMAINS; MUTATION; PATCH-CLAMP TECHNIQUES; PROTEIN TRANSPORT; RATS; RECOMBINANT FUSION PROTEINS;

EID: 40849145714     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.042093     Document Type: Article

References (51)

1. Abi-Char J, Maguy A, Coulombe A, Balse E, Ratajczak P, Samuel JL, Nattel S and Hatem SN (2007) Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J Physiol 582:1205-1217.
2. Anderson RG (1998) The caveolae membrane system. Annu Rev Biochem 67:199-225.
3. Armstrong CM and Hille B (1998) Voltage-gated ion channels and electrical excitability. Neuron 20:371-380.
4. Barbuti A, Gravante B, Riolfo M, Milanesi R, Terragni B, and DiFrancesco D (2004) Localization of pacemaker channels in lipid rafts regulates channel kinetics. Circ Res 94:1325-1331.
5. Benson MD, Li QJ, Kieckhafer K, Dudek D, Whorton MR, Sunahara RK, Iniguez-Lluhi JA, and Martens JR (2007) SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A 104:1805-1810.
6. Bönnemann CG and Finkel RS (2002) Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. Semin Pediatr Neurol 9:81-99.
7. 2+ influx channels by regulating plasma membrane localization of TRPC1. J Biol Chem 278:27208-27215.
8. Bush WS, Ihrke G, Robinson JM, and Kenworthy AK (2006) Antibody-specific detection of caveolin-1 in subapical compartments of MDCK cells. Histochem Cell Biol 126:27-34.
9. Cagliani R, Bresolin N, Prelle A, Gallanti A, Fortunato F, Sironi M, Ciscato P, Fagiolari G, Bonato S, Galbiati S, et al. (2003) A CAV3 microdeletion differentially affects skeletal muscle and myocardium. Neurology 61:1513-1519.
10. Cheng ZJ, Singh RD, Marks DL, and Pagano RE (2006) Membrane microdomains, caveolae, and caveolar endocytosis of sphingolipids. Mol Membr Biol 23:101-110.
11. + currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98:931-938.
12. Davies A, Douglas L, Hendrich J, Wratten J, Tran Van Minh A, Foucault I, Koch D, Pratt WS, Saibil HR, and Dolphin AC (2006) The calcium channel alpha2delta-2 subunit partitions with CaV2.1 into lipid rafts in cerebellum: implications for localization and function. J Neurosci 26:8748-8757.
13. Dubreuil RR, MacVicar G, Dissanayake S, Liu C, Homer D, and Hortsch M (1996) Neuroglian-mediated cell adhesion induces assembly of the membrane skeleton at cell contact sites. J Cell Biol 133:647-655.
14. Eldstrom J, Van Wagoner DR, Moore ED and Fedida D (2006) Localization of Kv1.5 channels in rat and canine myocyte sarcolemma. FEBS Lett 580:6039-6046.
15. Folco EJ, Liu GX, and Koren G (2004) Caveolin-3 and SAP97 form a scaffolding protein complex that regulates the voltage-gated potassium channel Kv1.5. Am J Physiol Heart Circ Physiol 287:H681-H690.
16. Galbiati F, Razani B, and Lisanti MP (2001) Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med 7:435-441.
17. Galbiati F, Volonte D, Minetti C, Bregman DB, and Lisanti MP (2000) Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutants and rescues wild-type caveolin-3. J Biol Chem 275:37702-37711.
18. Galbiati F, Volonte D, Minetti C, Chu JB, and Lisanti MP (1999) Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 274:25632-25641.
19. Harder T and Simons K (1997) Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 9:534-542.
20. Hayashi T, Arimura T, Ueda K, Shibata H, Hohda S, Takahashi M, Hori H, Koga Y, Oka N, Imaizumi T, et al. (2004) Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 313:178-184.
21. Hnasko R and Lisanti MP (2003) The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3:445-464.
22. Kwik J, Boyle S, Fooksman D, Margolis L, Sheetz MP, and Edidin M (2003) Membrane cholesterol, lateral mobility, and the phosphatidylinositol 4,5-bisphosphate-dependent organization of cell actin. Proc Natl Acad Sci U S A 100:13964-13969.
23. Maguy A, Hebert TE, and Nattel S (2006) Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc Res 69:798-807.
24. Martens JR, Navarro-Polanco R, Coppock EA, Nishiyama A, Parshley L, Grobaski TD, and Tamkun MM (2000) Differential targeting of Shaker-like potassium channels to lipid rafts. J Biol Chem 275:7443-7446.
25. Martens JR, O'Connell K, and Tamkun M (2004) Targeting of ion channels to membrane microdomains: localization of KV channels to lipid rafts. Trends Pharmacol Sci 25:16-21.
26. + channels to distinct lipid raft populations. Targeting of Kv1.5 to caveolae. J Biol Chem 276:8409-8414.
27. + channel protein in explanted cardiac tissue. J Clin Invest 96:282-292.
28. McEwen DP, Schumacher SM, Li Q, Benson MD, Iniguez-Lluhi JA, Van Genderen KM, and Martens JR (2007) Rab-GTPase-dependent endocytic recycling of KV1.5 in atrial myocytes. J Biol Chem 282:29612-29620.
29. McNally EM, de Sa Moreira E, Duggan DJ, Bonnemann CG, Lisanti MP, Lidov HG, Vainzof M, Passos-Bueno MR, Hoffman EP, Zatz M, et al. (1998) Caveolin-3 in muscular dystrophy. Hum Mol Genet 7:871-877.
30. Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG, and Brown DA (1999) Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J Biol Chem 274:3910-3917.
31. Michelakis ED and Weir EK (2001) The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels. Clin Chest Med 22:419-432.
32. + channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 13:615-632.
33. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, and Simons K (1995) VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 92:10339-10343.
34. O'Connell KM, Martens JR, and Tamkun MM (2004) Localization of ion channels to lipid Raft domains within the cardiovascular system. Trends Cardiovasc Med 14:37-42.
35. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP (1998) Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273:5419-5422.
36. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, and Terzic A (2006) Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 15:2185-2191.
37. Parton RG and Simons K (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8:185-194.
38. Pottosin II, Valencia-Cruz G, Bonales-Alatorre E, Shabala SN, and Dobrovinskaya OR (2007) Methyl-beta-cyclodextrin reversibly alters the gating of lipid rafts-associated Kv1.3 channels in Jurkat T lymphocytes. Pflugers Arch 454:235-244.
39. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, et al. (2007) Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292:C1837-C1853.
40. Rolf S, Haverkamp W, Borggrefe M, Musshoff U, Eckardt L, Mergenthaler J, Snyders DJ, Pongs O, Speckmann EJ, Breithardt G, et al. (2000) Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol 362:22-31.
41. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, and Parton RG (1999) Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1:98-105.
42. Schlegel A, Volonte D, Engelman JA, Galbiati F, Mehta P, Zhang XL, Scherer PE, and Lisanti MP (1998) Crowded little caves: structure and function of caveolae. Cell Signal 10:457-463.
43. Simons K and Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569-572.
44. Tanabe Y, Hatada K, Naito N, Aizawa Y, Chinushi M, and Nawa H (2006) Overexpression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation. Biochem Biophys Res Commun 345:1116-1121.
45. Uittenbogaard A and Smart EJ (2000) Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J Biol Chem 275:25595-25599.
46. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80:772-781.
47. Vorgerd M, Ricker K, Ziemssen F, Kress W, Goebel HH, Nix WA, Kubisch C, Schoser BG, and Mortier W (2001) A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 57:2273-2277.
48. Woodman SE, Sotgia F, Galbiati F, Minetti C, and Lisanti MP (2004) Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62:538-543.
49. Wyse BD, Prior IA, Qian H, Morrow IC, Nixon S, Muncke C, Kurzchalia TV, Thomas WG, Parton RG, and Hancock JF (2003) Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 278:23738-23746.
50. Zhang L, Foster K, Li Q, and Martens JR (2007) S-acylation regulates Kv1.5 channel surface expression. Am J Physiol Cell Physiol 293:C152-C161.
51. Zhang W, Trible RP, and Samelson LE (1998) LAT palmitoylation: its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation. Immunity 9:239-246.